CD4 and neoplasm: Here we have demonstrated that for obinutuzumab, when given in combination with a systemic TLR7 agonist, long-term tumor-free survival appears to be dependent on NK cells and CD4+ T cells with macrophages and monocytes only able to mediate short-term increases in survival.